Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study

Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation and placement; 2) it allows for continuous hemodynamic monitoring through a distal optical fiber sensor; and 3) it enables wire pacing through the left ventricle.

pacemaker marcapasos definitivo

The objective of the prospective multicenter SAFE-TAVI (SavvyWire Efficacy and Safety in Transcatheter Aortic Valve Implantation Procedures) Study was to assess the safety and efficacy of the SavyWire in TAVR with both balloon-expandable and self-expandable valves.

The primary endpoint (PEP) was rapid and effective pacing with a significant drop in pressure (reduction of systolic pressure below 60 mmHg). The secondary safety endpoint (SSE) was absence of guidewire-related major complications.

The analysis included 119 patients; the mean age was 82.2 ± 5.9 years, and 49.6% of subjects were women. The mean STS score was 3.85. All patients were treated using the transfemoral access. Balloon-expandable valves were used in 37.8% of cases, with predilation performed in 74.8% and postdilation in 11.8% of patients.

Read also: Use of IVL in Calcified Coronary Lesions in a Real World Population.

Regarding the PEP, 98.3% of patients showed a drop in systolic pressure below 60 mmHg, with a mean arterial systolic pressure during rapid pacing of 46.6±11.3 mmHg. The SSE was achieved in 99.2% of cases, with no mortality, stroke, guidewire kinking, or ventricular perforation events.

Conclusion

The results of this study demonstrate the safety and efficacy of the SavyWire during TAVR. This device may contribute to minimizing intervention during the procedure and improving clinical outcomes after TAVR implantation.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Safety and Efficacy of Transcatheter Aortic Valve Replacement With a Pressure Sensor and Pacing Guidewire SAFE-TAVI Trial.

Reference: Ander Regueiro, MD, PHD et al J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

 The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...